Parkinson's disease and noradrenergic system

被引：0
|
作者：
Brefel-Courbon, C [1 ]
机构：
[1] Hop Toulouse, Serv Pharmacol Clin, Fac Med, F-31073 Toulouse, France
来源：
PRESSE MEDICALE | 2002年 / 31卷 / 26期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1240 / 1242
页数：3
相关论文
共 50 条
  • [41] Exploring Parkinson's Disease-Associated Depression: Role of Inflammation on the Noradrenergic and Serotonergic Pathways
    Sampaio, Tuane Bazanella
    Schamne, Marissa Giovanna
    Santos, Jean Rodrigo
    Ferro, Marcelo Machado
    Miyoshi, Edmar
    Prediger, Rui Daniel
    BRAIN SCIENCES, 2024, 14 (01)
  • [42] Loss of noradrenergic neurons in the locus coeruleus of Parkinson's disease subjects does not result in compensation
    Szot, P.
    Franklin, A.
    White, S.
    Raskind, M.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S166 - S166
  • [43] The anti-inflammatory actions of noradrenergic agents as a target to prevent neurodegeneration in Parkinson's disease
    Yssel, Justin
    Connor, Thomas
    Harkin, Andrew
    JOURNAL OF NEUROIMMUNOLOGY, 2014, 275 (1-2) : 122 - 123
  • [44] Modelling the dopamine and noradrenergic cell loss that occurs in Parkinson's disease and the impact on hippocampal neurogenesis
    Ermine, Charlotte M.
    Wright, Jordan L.
    Frausin, Stefano
    Kauhausen, Jessica A.
    Parish, Clare L.
    Stanic, Davor
    Thompson, Lachlan H.
    HIPPOCAMPUS, 2018, 28 (05) : 327 - 337
  • [45] Interaction of Noradrenergic Pharmacological Manipulation and Subthalamic Stimulation on Movement Initiation Control in Parkinson's Disease
    Albares, Marion
    Thobois, Sephane
    Favre, Emilie
    Broussolle, Emmanuel
    Polo, Gustavo
    Domenech, Philippe
    Boulinguez, Philippe
    Ballanger, Benedicte
    BRAIN STIMULATION, 2015, 8 (01) : 27 - 35
  • [46] Noradrenergic System in Down Syndrome and Alzheimer's Disease A Target for Therapy
    Phillips, Cristy
    Fahimi, Atoossa
    Das, Devsmita
    Mojabi, Fatemeh S.
    Ponnusamy, Ravikumar
    Salehi, Ahmad
    CURRENT ALZHEIMER RESEARCH, 2016, 13 (01) : 68 - 83
  • [47] Noradrenergic modulation of movement initiation control in Parkinson's disease: A pharmacological fMRI study with clonidine
    Ballanger, B.
    Criaud, M.
    Poisson, A.
    Metereau, E.
    Redoute, J.
    Ibarrola, D.
    Broussolle, E.
    Thobois, S.
    Boulinguez, P.
    MOVEMENT DISORDERS, 2014, 29 : S134 - S135
  • [48] Targeting the cholinergic system in Parkinson’s disease
    Changliang Liu
    Acta Pharmacologica Sinica, 2020, 41 : 453 - 463
  • [49] Targeting the cholinergic system in Parkinson's disease
    Liu, Changliang
    ACTA PHARMACOLOGICA SINICA, 2020, 41 (04): : 453 - 463
  • [50] Smell in Parkinson's disease, and the dopaminergic system
    Radil, T
    Roth, J
    Ruzicka, E
    Tichy, J
    Wysocki, CJ
    INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY, 1998, 30 (1-2) : 39 - 39
12345